A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Japanese Patients With DSM-IV-TR Schizophrenia.

Trial Profile

A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Japanese Patients With DSM-IV-TR Schizophrenia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 May 2016

At a glance

  • Drugs Pomaglumetad methionil (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
    • 17 Nov 2011 Planned end date changed from 1 Jun 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 14 Oct 2010 Planned end date changed from 1 Feb 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top